Literature DB >> 24710565

Feasibility of umbilical cord blood transplantation with a myeloablative, reduced toxicity-conditioning regimen.

M Nishimoto1, H Nakamae1, M Nakamae1, A Hirose1, K Hagihara1, H Koh1, T Nakane1, Y Terada1, M Hino1.   

Abstract

Entities:  

Mesh：

Year:  2014        PMID： 24710565     DOI： 10.1038/bmt.2014.60

Source DB:  PubMed          Journal:  Bone Marrow Transplant        ISSN： 0268-3369            Impact factor:   5.483


× No keyword cloud information.
  10 in total

1.  High incidence of graft failure in unrelated cord blood transplantation using a reduced-intensity preparative regimen consisting of fludarabine and melphalan.

Authors:  H Narimatsu; M Watanabe; A Kohno; K Sugimoto; Y Kuwatsuka; T Uchida; M Murata; K Miyamura; Y Morishita
Journal:  Bone Marrow Transplant       Date:  2008-01-14       Impact factor: 5.483

2.  Comparison between two fludarabine-based reduced-intensity conditioning regimens before allogeneic hematopoietic stem-cell transplantation: fludarabine/melphalan is associated with higher incidence of acute graft-versus-host disease and non-relapse mortality and lower incidence of relapse than fludarabine/busulfan.

Authors:  A Shimoni; I Hardan; N Shem-Tov; A Rand; C Herscovici; R Yerushalmi; A Nagler
Journal:  Leukemia       Date:  2007-08-09       Impact factor: 11.528

Review 3.  Reduced-intensity conditioning and umbilical cord blood transplantation in adults.

Authors:  C Cutler; K Ballen
Journal:  Bone Marrow Transplant       Date:  2009-10-05       Impact factor: 5.483

4.  Conditioning therapy with intravenous busulfan and cyclophosphamide (IV BuCy2) for hematologic malignancies prior to allogeneic stem cell transplantation: a phase II study.

Authors:  Borje S Andersson; Ashwin Kashyap; Victor Gian; John R Wingard; Hugo Fernandez; Pablo J Cagnoni; Roy B Jones; Stefano Tarantolo; Wendy W Hu; Karl G Blume; Stephen J Forman; Richard E Champlin
Journal:  Biol Blood Marrow Transplant       Date:  2002       Impact factor: 5.742

5.  High busulfan concentrations are associated with increased transplant-related mortality in allogeneic bone marrow transplant patients.

Authors:  P Ljungman; M Hassan; A N Békássy; O Ringdén; G Oberg
Journal:  Bone Marrow Transplant       Date:  1997-12       Impact factor: 5.483

6.  Rapid and complete donor chimerism in adult recipients of unrelated donor umbilical cord blood transplantation after reduced-intensity conditioning.

Authors:  Juliet N Barker; Daniel J Weisdorf; Todd E DeFor; Bruce R Blazar; Jeffrey S Miller; John E Wagner
Journal:  Blood       Date:  2003-05-08       Impact factor: 22.113

7.  Infectious complications after unrelated umbilical cord blood transplantation in adult patients with hematologic malignancies.

Authors:  Xavier Cahu; Fanny Rialland; Cyrille Touzeau; Patrice Chevallier; Thierry Guillaume; Jacques Delaunay; Sameh Ayari; Viviane Dubruille; Steven Le Gouill; Beatrice Mahe; Thomas Gastinne; Nicolas Blin; Beatrice Saulquin; Jean-Luc Harousseau; Philippe Moreau; Mohamad Mohty
Journal:  Biol Blood Marrow Transplant       Date:  2009-09-25       Impact factor: 5.742

8.  Umbilical cord blood transplantation after nonmyeloablative conditioning: impact on transplantation outcomes in 110 adults with hematologic disease.

Authors:  Claudio G Brunstein; Juliet N Barker; Daniel J Weisdorf; Todd E DeFor; Jeffrey S Miller; Bruce R Blazar; Philip B McGlave; John E Wagner
Journal:  Blood       Date:  2007-06-14       Impact factor: 22.113

9.  Umbilical cord blood transplantation after reduced-intensity conditioning for elderly patients with hematologic diseases.

Authors:  Naoyuki Uchida; Atsushi Wake; Shinsuke Takagi; Hisashi Yamamoto; Daisuke Kato; Yoshiko Matsuhashi; Tomoko Matsumura; Sachiko Seo; Naofumi Matsuno; Kazuhiro Masuoka; Eiji Kusumi; Koichiro Yuji; Shigesaburo Miyakoshi; Michio Matsuzaki; Akiko Yoneyama; Shuichi Taniguchi
Journal:  Biol Blood Marrow Transplant       Date:  2008-05       Impact factor: 5.742

10.  Myeloablative intravenous busulfan/fludarabine conditioning does not facilitate reliable engraftment of dual umbilical cord blood grafts in adult recipients.

Authors:  Mitchell E Horwitz; Ashley Morris; Cristina Gasparetto; Keith Sullivan; Gwynn Long; John Chute; David Rizzieri; Jackie McPherson; Nelson Chao
Journal:  Biol Blood Marrow Transplant       Date:  2008-05       Impact factor: 5.742
  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.